- Conditions
- Adult Acute Myeloid Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Interventions
- filgrastim, Anti-Thymocyte Globulin, busulfan, fludarabine phosphate, methotrexate, tacrolimus, Allogeneic Hematopoietic Stem Cell Transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 60 Years to 74 Years
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2016
- U.S. locations
- 21
- States / cities
- San Francisco, California • Lewes, Delaware • Newark, Delaware + 13 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1609–1632
of 21,531
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Ficerafusp alfa, Pembrolizumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Advanced Solid Tumors
- Interventions
- TAS-102
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Duarte, California • Santa Monica, California + 6 more
- Conditions
- Human Immunodeficiency Virus Type 1
- Interventions
- D/C/F/TAF, Boosted Protease Inhibitor (bPI), FTC/TDF
- Drug
- Lead sponsor
- Janssen R&D Ireland
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 35 more
- Conditions
- Hydroxocobalamin Adverse Reaction
- Interventions
- Hydroxocobalamin
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hypertension
- Interventions
- Eplerenone
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 6 Years to 16 Years
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 28
- States / cities
- Little Rock, Arkansas • Beverly Hills, California • Inglewood, California + 25 more
- Conditions
- Osteoporosis, Postmenopausal, Osteoporosis
- Interventions
- denosumab, alendronate, raloxifene
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 45 Years and older · Female only
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer, Cancer
- Interventions
- Venetoclax, Capecitabine
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 11
- States / cities
- Joliet, Illinois • Boston, Massachusetts • Minneapolis, Minnesota + 7 more
- Conditions
- Cardiac Arrhythmia
- Interventions
- PURE EP 2
- Device
- Lead sponsor
- BioSig Technologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 3
- States / cities
- Jacksonville, Florida • Boston, Massachusetts • Austin, Texas
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Afrezza, insulin degludec, Rapid-acting Insulin Analog, Basal Insulin
- Biological
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 19
- States / cities
- Loma Linda, California • Santa Barbara, California • Aurora, Colorado + 15 more
- Conditions
- Intrauterine Growth Retardation, Prematurity
- Interventions
- Newborn Individualized Developmental Care
- Behavioral
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- Up to 36 Weeks
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2002
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Thrombocytopenia Associated With Liver Disease
- Interventions
- avatrombopag (lower baseline platelet count), placebo (lower baseline platelet count), avatrombopag (higher baseline platelet count), placebo (higher baseline platelet count)
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 20 more
- Conditions
- Asthma, Atopy
- Interventions
- fluticasone, Placebo
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 9
- States / cities
- San Francisco, California • Denver, Colorado • Chicago, Illinois + 6 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Zanubrutinib, Bendamustine, Rituximab, Venetoclax
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 18
- States / cities
- Augusta, Georgia • Chicago, Illinois • Boston, Massachusetts + 13 more
- Conditions
- Neurotrophic Keratitis
- Interventions
- rhNGF 20µg/ml, Placebo
- Drug · Other
- Lead sponsor
- Dompé Farmaceutici S.p.A
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 12
- States / cities
- Loma Linda, California • Los Angeles, California • San Diego, California + 8 more
- Conditions
- Breast Cancer
- Interventions
- rosuvastatin
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Coronary Artery Disease, Atrial Fibrillation, Type 2 Diabetes, Colorectal Cancer, Breast Cancer, Prostate Cancer
- Interventions
- Polygenic risk score (PRS)
- Diagnostic Test
- Lead sponsor
- Boston VA Research Institute, Inc.
- Other
- Eligibility
- 50 Years to 70 Years
- Enrollment
- 1,071 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Pancreatic Cancer
- Interventions
- BPM31510 Nanosuspension Injection, Gemcitabine
- Drug
- Lead sponsor
- BPGbio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 9
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Gilroy, California + 6 more
- Conditions
- Melanoma
- Interventions
- CMP-001, Pembrolizumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Duarte, California + 9 more
- Conditions
- Cerebellar Neoplasm
- Interventions
- Medoc Advanced Medical Systems PATHWAY Model ATS, Cold water bath, MRI scanner, Questionnaires
- Device · Procedure · Other
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 6 Years to 38 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Caregiver, Hematologic Malignancy
- Interventions
- Positive Psychology Intervention
- Behavioral
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes, Diabetes Mellitus, Type 1
- Interventions
- Faster-acting insulin aspart, insulin aspart, insulin degludec
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 834 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Long Beach, California + 32 more
- Conditions
- Enteritis
- Interventions
- SGX201 (delayed release beclomethasone 17,21-dipropionate)
- Drug
- Lead sponsor
- Soligenix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Boston, Massachusetts
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- sacubitril/valsartan, Enalapril, Valsartan, Placebo to match sacubitril/valsartan, Placebo to match enalapril, Placebo to match valsartan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 2,572 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 32
- States / cities
- Andalusia, Alabama • Mobile, Alabama • Beverly Hills, California + 29 more